# Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 8.7 | 80.6 | (32.3-166.1) |  | Male | 14 | 5.7 | 246.5 | (134.7-413.7) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 5 | 5.0 | 99.4 | (32.0-231.9) |
| Female | 36 | 31.8 | 113.3 | (79.4-156.9) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 9.5 | 84.5 | (36.4-166.6) |  |  |  |  |  |  |
| Female | 6 | 7.8 | 77.2 | (28.2-168.1) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 33 | 32.9 | 100.4 | (69.1-140.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 5.0 | nc | (nc-nc) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.4 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 7 | 5.6 | 125.5 | (50.3-258.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 9 | 7.5 | 120.5 | (55.0-228.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 11 | 16.1 | 68.2 | (34.0-122.1) |  | Male | 109 | 119.2 | 91.5 | (75.1-110.4) |
| Female | 9 | 15.0 | 60.2 | (27.5-114.2) |  | Female | 95 | 103.7 | 91.7 | (74.1-112.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

214

# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 20.6 | 92.0 | (55.4-143.7) |  | Male | 29 | 13.4 | 216.3 | (144.8-310.7) |
| Female | 7 | 8.4 | 83.1 | (33.3-171.3) |  | Female | 18 | 11.6 | 155.7 | (92.3-246.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 6 | 3.8 | 156.2 | (57.0-340.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 18 | 11.9 | 151.6 | (89.8-239.7) |
| Female | 95 | 93.4 | 101.7 | (82.3-124.4) |  | Female | 8 | 11.7 | 68.3 | (29.4-134.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 10.1 | 118.5 | (61.2-207.0) |
| Female | 0 | 2.9 | nc | (nc-nc) |  | Female | 4 | 5.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 22.5 | 106.7 | (68.4-158.8) |  |  |  |  |  |  |
| Female | 27 | 24.7 | 109.4 | (72.1-159.2) |  | Female | 5 | 8.3 | 60.2 | (19.4-140.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 5.7 | 104.4 | (38.1-227.3) |  | Male | 9 | 7.4 | 121.0 | (55.2-229.7) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 9 | 8.4 | 107.0 | (48.8-203.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 85 | 76.2 | 111.6 | (89.1-138.0) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 11.8 | 76.5 | (34.9-145.2) |  | Male | 6 | 4.9 | 122.4 | (44.7-266.3) |
| Female | 3 | 7.4 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 8.1 | 61.6 | (19.9-143.9) |  | Male | 11 | 5.2 | 212.4 | (105.9-380.1) |
| Female | 1 | 6.6 | nc | (nc-nc) |  | Female | 21 | 15.7 | 133.6 | (82.7-204.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 22 | 22.3 | 98.5 | (61.7-149.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 37.9 | 58.1 | (36.4-87.9) |  | Male | 287 | 280.1 | 102.5 | (91.0-115.0) |
| Female | 40 | 45.5 | 87.9 | (62.8-119.8) |  | Female | 307 | 313.9 | 97.8 | (87.2-109.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

215

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 88 | 102.1 | 86.2 | (69.1-106.2) |  | Male | 69 | 62.6 | 110.3 | (85.8-139.6) |
| Female | 46 | 35.1 | 130.9 | (95.8-174.6) |  | Female | 62 | 48.3 | 128.4 | (98.4-164.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 24 | 18.0 | 133.2 | (85.3-198.2) |  | Male | 26 | 19.9 | 130.6 | (85.3-191.3) |
| Female | 16 | 15.4 | 104.0 | (59.4-168.9) |  | Female | 18 | 15.7 | 114.5 | (67.8-180.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.4 | nc | (nc-nc) |  | Male | 61 | 56.2 | 108.6 | (83.1-139.5) |
| Female | 437 | 375.2 | 116.5 | (105.8-127.9) |  | Female | 53 | 48.5 | 109.2 | (81.8-142.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 30 | 43.2 | 69.5 | (46.9-99.2) |
| Female | 10 | 12.5 | 79.7 | (38.2-146.6) |  | Female | 28 | 20.4 | 137.2 | (91.2-198.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 92 | 107.0 | 86.0 | (69.3-105.5) |  |  |  |  |  |  |
| Female | 82 | 105.9 | 77.4 | (61.6-96.1) |  | Female | 38 | 33.7 | 112.6 | (79.7-154.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 25.8 | 42.6 | (21.2-76.3) |  | Male | 34 | 35.0 | 97.0 | (67.2-135.6) |
| Female | 9 | 6.8 | 132.7 | (60.6-251.9) |  | Female | 51 | 35.4 | 143.9 | (107.1-189.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 6.9 | nc | (nc-nc) |  | Male | 341 | 320.1 | 106.5 | (95.5-118.4) |
| Female | 3 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 56 | 51.6 | 108.5 | (81.9-140.9) |  | Male | 20 | 23.3 | 85.7 | (52.3-132.3) |
| Female | 21 | 30.1 | 69.7 | (43.2-106.6) |  | Female | 14 | 13.7 | 102.3 | (55.9-171.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 14.8 | 67.6 | (32.4-124.4) |  | Male | 11 | 11.7 | 93.8 | (46.8-167.9) |
| Female | 1 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 41 | 39.5 | 103.8 | (74.5-140.9) |  | Male | 34 | 22.4 | 152.1 | (105.3-212.5) |
| Female | 22 | 28.7 | 76.6 | (48.0-115.9) |  | Female | 81 | 68.0 | 119.1 | (94.6-148.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 31 | 32.8 | 94.4 | (64.1-134.0) |  |  |  |  |  |  |
| Female | 9 | 11.0 | 81.5 | (37.2-154.7) |  | Female | 91 | 85.7 | 106.2 | (85.5-130.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 130 | 177.9 | 73.1 | (61.0-86.8) |  | Male | 1189 | 1278.0 | 93.0 | (87.8-98.5) |
| Female | 158 | 182.0 | 86.8 | (73.8-101.5) |  | Female | 1370 | 1288.7 | 106.3 | (100.8-112.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

216

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 11.2 | 62.3 | (24.9-128.3) |  | Male | 12 | 8.5 | 140.6 | (72.6-245.7) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 7 | 4.3 | 161.5 | (64.7-332.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.8 | nc | (nc-nc) |  | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 8 | 7.7 | 104.5 | (45.0-205.9) |
| Female | 46 | 36.0 | 127.9 | (93.6-170.6) |  | Female | 0 | 3.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 13.9 | 79.2 | (39.5-141.7) |  |  |  |  |  |  |
| Female | 8 | 7.8 | 103.1 | (44.4-203.2) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 44 | 49.3 | 89.3 | (64.9-119.9) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 8.1 | 74.1 | (27.1-161.4) |  | Male | 6 | 2.9 | 205.2 | (74.9-446.6) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 5.1 | 118.1 | (43.1-257.1) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 8 | 7.1 | 112.7 | (48.5-222.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 7 | 8.5 | 82.6 | (33.1-170.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 21.5 | 88.5 | (53.2-138.2) |  | Male | 149 | 176.5 | 84.4 | (71.4-99.1) |
| Female | 12 | 14.2 | 84.3 | (43.5-147.3) |  | Female | 113 | 111.4 | 101.4 | (83.6-121.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

217

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 17.1 | 105.4 | (62.4-166.5) |  | Male | 6 | 10.4 | 57.6 | (21.0-125.4) |
| Female | 12 | 5.9 | 202.8 | (104.6-354.2) |  | Female | 8 | 7.8 | 102.5 | (44.1-201.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 3.0 | nc | (nc-nc) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 12 | 9.3 | 129.1 | (66.6-225.5) |
| Female | 52 | 60.6 | 85.8 | (64.1-112.5) |  | Female | 7 | 8.0 | 88.0 | (35.3-181.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.9 | 72.8 | (23.5-169.9) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 17.6 | 153.3 | (101.0-223.0) |  |  |  |  |  |  |
| Female | 22 | 17.3 | 127.1 | (79.7-192.5) |  | Female | 6 | 5.4 | 110.4 | (40.3-240.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 4.2 | 191.5 | (82.5-377.3) |  | Male | 0 | 5.7 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 10 | 5.9 | 169.6 | (81.2-311.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 51 | 49.7 | 102.6 | (76.4-134.9) |
| Female | 1 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 8.3 | 167.7 | (91.6-281.5) |  | Male | 6 | 3.9 | 155.8 | (56.9-339.1) |
| Female | 2 | 5.0 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 4 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.6 | 90.9 | (33.2-197.8) |  | Male | 3 | 3.7 | nc | (nc-nc) |
| Female | 5 | 4.7 | 107.0 | (34.5-249.7) |  | Female | 9 | 10.7 | 84.4 | (38.5-160.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 11 | 5.2 | 209.6 | (104.5-375.1) |  |  |  |  |  |  |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 12 | 13.7 | 87.9 | (45.4-153.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 29.7 | 114.5 | (79.3-160.0) |  | Male | 230 | 208.2 | 110.5 | (96.7-125.7) |
| Female | 47 | 31.4 | 149.8 | (110.0-199.2) |  | Female | 223 | 210.8 | 105.8 | (92.4-120.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

218

# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 28.9 | 121.1 | (84.3-168.4) |  | Male | 18 | 18.8 | 95.5 | (56.6-151.0) |
| Female | 13 | 11.5 | 112.7 | (59.9-192.7) |  | Female | 12 | 15.7 | 76.3 | (39.4-133.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.8 | 102.9 | (37.6-224.1) |  | Male | 5 | 5.8 | 85.5 | (27.5-199.5) |
| Female | 7 | 4.9 | 142.4 | (57.1-293.4) |  | Female | 5 | 5.1 | 97.9 | (31.6-228.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 19 | 17.0 | 111.8 | (67.3-174.7) |
| Female | 117 | 123.4 | 94.8 | (78.4-113.6) |  | Female | 17 | 15.8 | 107.8 | (62.8-172.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 13.7 | 80.4 | (40.1-143.8) |
| Female | 5 | 4.2 | 119.9 | (38.6-279.7) |  | Female | 5 | 6.6 | 75.8 | (24.4-176.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 32.0 | 90.6 | (60.6-130.1) |  |  |  |  |  |  |
| Female | 45 | 35.2 | 128.0 | (93.3-171.2) |  | Female | 9 | 10.9 | 82.4 | (37.6-156.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.6 | 91.9 | (36.8-189.4) |  | Male | 13 | 10.2 | 127.5 | (67.8-218.0) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 9 | 11.6 | 77.4 | (35.3-147.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 102 | 94.6 | 107.8 | (87.9-130.9) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 19 | 16.0 | 118.7 | (71.4-185.4) |  | Male | 8 | 6.8 | 117.1 | (50.4-230.8) |
| Female | 7 | 9.8 | 71.2 | (28.5-146.7) |  | Female | 6 | 4.6 | 131.4 | (48.0-286.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 4.4 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 11.9 | 83.7 | (40.1-154.0) |  | Male | 10 | 7.5 | 133.0 | (63.7-244.6) |
| Female | 10 | 9.3 | 107.0 | (51.2-196.8) |  | Female | 27 | 22.4 | 120.7 | (79.5-175.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 10.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 22 | 27.1 | 81.2 | (50.9-123.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 50.8 | 70.8 | (49.6-98.1) |  | Male | 375 | 380.0 | 98.7 | (89.0-109.2) |
| Female | 52 | 59.2 | 87.8 | (65.6-115.2) |  | Female | 407 | 421.2 | 96.6 | (87.5-106.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

219

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 23.1 | 90.7 | (56.1-138.7) |  | Male | 17 | 16.3 | 104.1 | (60.6-166.7) |
| Female | 7 | 8.2 | 85.1 | (34.1-175.4) |  | Female | 22 | 13.4 | 164.2 | (102.9-248.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.5 | 108.8 | (39.7-236.8) |  | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 8 | 4.3 | 185.5 | (79.9-365.6) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 17 | 14.7 | 115.6 | (67.3-185.1) |
| Female | 103 | 104.5 | 98.5 | (80.4-119.5) |  | Female | 14 | 12.2 | 114.4 | (62.5-191.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 12.7 | 86.9 | (43.3-155.5) |
| Female | 2 | 4.0 | nc | (nc-nc) |  | Female | 8 | 5.3 | 151.7 | (65.3-298.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 26.9 | 122.8 | (84.5-172.5) |  |  |  |  |  |  |
| Female | 26 | 26.2 | 99.4 | (64.9-145.6) |  | Female | 5 | 9.1 | 55.2 | (17.8-128.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 6.7 | 119.8 | (51.6-236.1) |  | Male | 6 | 8.6 | 70.1 | (25.6-152.5) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 10 | 8.3 | 120.6 | (57.7-221.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 96 | 88.7 | 108.3 | (87.7-132.2) |
| Female | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 14.8 | 94.7 | (51.7-159.0) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 6 | 7.9 | 75.7 | (27.6-164.7) |  | Female | 2 | 3.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 4.0 | 201.9 | (86.9-397.8) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 10.3 | 58.0 | (21.2-126.3) |  | Male | 6 | 7.3 | 81.7 | (29.8-177.7) |
| Female | 5 | 7.4 | 67.2 | (21.7-156.8) |  | Female | 27 | 21.8 | 123.9 | (81.6-180.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 9.1 | 110.0 | (52.7-202.4) |  |  |  |  |  |  |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 21 | 22.9 | 91.7 | (56.8-140.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 45 | 42.9 | 105.0 | (76.6-140.5) |  | Male | 347 | 334.5 | 103.7 | (93.1-115.2) |
| Female | 47 | 43.8 | 107.4 | (78.9-142.8) |  | Female | 342 | 339.8 | 100.7 | (90.3-111.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

220

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 4.3 | nc | (nc-nc) |  | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 15 | 20.7 | 72.5 | (40.6-119.6) |  | Female | 4 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 5 | 5.5 | 91.1 | (29.4-212.6) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 18 | 15.6 | 115.5 | (68.4-182.6) |
| Female | 2 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 3.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 8.2 | 97.7 | (42.1-192.5) |  | Male | 64 | 60.9 | 105.2 | (81.0-134.3) |
| Female | 5 | 9.6 | 52.0 | (16.8-121.3) |  | Female | 57 | 68.6 | 83.1 | (63.0-107.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

221

# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 14.4 | 76.5 | (38.1-136.9) |  | Male | 16 | 9.8 | 163.0 | (93.1-264.8) |
| Female | 8 | 5.2 | 153.9 | (66.3-303.4) |  | Female | 13 | 8.1 | 160.7 | (85.5-274.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.1 | 160.3 | (51.6-374.0) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 0 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 8 | 8.8 | 90.6 | (39.0-178.4) |
| Female | 76 | 65.9 | 115.4 | (90.9-144.4) |  | Female | 5 | 7.6 | 65.6 | (21.1-153.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 7.6 | 66.0 | (21.3-154.0) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 1 | 3.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 16.3 | 85.6 | (46.8-143.7) |  |  |  |  |  |  |
| Female | 15 | 16.1 | 93.4 | (52.2-154.1) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 4.1 | 217.7 | (99.4-413.3) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 50 | 54.8 | 91.2 | (67.7-120.2) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 8.9 | 101.4 | (46.2-192.4) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 3 | 5.0 | nc | (nc-nc) |  | Female | 0 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.4 | 205.4 | (66.2-479.3) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 6.0 | 198.5 | (102.4-346.7) |  | Male | 4 | 4.3 | nc | (nc-nc) |
| Female | 7 | 4.3 | 162.0 | (64.9-333.7) |  | Female | 16 | 12.5 | 128.1 | (73.2-208.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 5.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.7 | nc | (nc-nc) |  | Female | 18 | 14.7 | 122.4 | (72.5-193.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 19 | 26.5 | 71.7 | (43.1-112.0) |  | Male | 201 | 203.6 | 98.7 | (85.5-113.4) |
| Female | 23 | 29.0 | 79.3 | (50.2-118.9) |  | Female | 214 | 211.9 | 101.0 | (87.9-115.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

222

# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 32 | 29.4 | 108.7 | (74.3-153.5) |  | Male | 12 | 18.8 | 63.7 | (32.9-111.3) |
| Female | 10 | 11.1 | 90.1 | (43.1-165.7) |  | Female | 12 | 16.1 | 74.4 | (38.4-130.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 5.5 | 108.4 | (39.6-235.9) |  | Male | 1 | 6.0 | nc | (nc-nc) |
| Female | 6 | 5.1 | 118.8 | (43.4-258.6) |  | Female | 9 | 5.0 | 180.4 | (82.3-342.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 15 | 16.9 | 89.0 | (49.8-146.8) |
| Female | 153 | 119.9 | 127.6 | (108.2-149.5) |  | Female | 18 | 15.6 | 115.6 | (68.5-182.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 13.6 | 110.3 | (61.7-182.0) |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 8 | 6.5 | 122.2 | (52.6-240.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 31 | 31.5 | 98.5 | (66.9-139.8) |  |  |  |  |  |  |
| Female | 35 | 33.6 | 104.1 | (72.5-144.7) |  | Female | 15 | 11.0 | 136.4 | (76.3-225.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 7.9 | 63.0 | (20.3-147.1) |  | Male | 9 | 10.4 | 86.9 | (39.7-165.0) |
| Female | 5 | 2.2 | 232.3 | (74.8-542.0) |  | Female | 14 | 11.2 | 124.6 | (68.0-209.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 68 | 103.0 | 66.0 | (51.3-83.7) |
| Female | 2 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 16.2 | 55.4 | (25.3-105.2) |  | Male | 5 | 6.9 | 72.8 | (23.5-169.8) |
| Female | 9 | 9.5 | 94.4 | (43.1-179.2) |  | Female | 4 | 4.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.6 | nc | (nc-nc) |  | Male | 6 | 4.0 | 151.6 | (55.3-329.9) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 11.6 | 112.5 | (59.8-192.4) |  | Male | 5 | 7.3 | 68.4 | (22.0-159.7) |
| Female | 10 | 9.2 | 108.7 | (52.0-199.9) |  | Female | 11 | 23.5 | 46.7 | (23.3-83.6) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 10.1 | 69.4 | (27.8-143.0) |  |  |  |  |  |  |
| Female | 1 | 3.5 | nc | (nc-nc) |  | Female | 33 | 27.6 | 119.5 | (82.2-167.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 47 | 52.8 | 89.1 | (65.5-118.5) |  | Male | 313 | 389.3 | 80.4 | (71.7-89.8) |
| Female | 56 | 56.9 | 98.4 | (74.3-127.8) |  | Female | 451 | 413.8 | 109.0 | (99.2-119.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

223

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 15.2 | 132.0 | (80.6-203.9) |  | Male | 9 | 9.9 | 91.0 | (41.5-172.7) |
| Female | 9 | 5.4 | 166.5 | (76.0-316.1) |  | Female | 6 | 7.7 | 78.1 | (28.5-170.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 5 | 8.9 | 56.0 | (18.1-130.7) |
| Female | 71 | 59.7 | 118.9 | (92.9-150.0) |  | Female | 3 | 7.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 7.4 | nc | (nc-nc) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 17.0 | 70.8 | (36.5-123.7) |  |  |  |  |  |  |
| Female | 15 | 17.0 | 88.1 | (49.3-145.3) |  | Female | 3 | 5.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.0 | 148.7 | (54.3-323.6) |  | Male | 5 | 5.4 | 92.6 | (29.8-216.0) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 7 | 5.5 | 127.3 | (51.0-262.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 48 | 51.3 | 93.6 | (69.0-124.1) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 8.5 | 70.6 | (25.8-153.7) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 5 | 4.7 | 106.0 | (34.1-247.3) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 6.2 | 193.7 | (100.0-338.4) |  | Male | 2 | 3.9 | nc | (nc-nc) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 8 | 11.0 | 72.4 | (31.2-142.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 5.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 21 | 13.3 | 157.7 | (97.6-241.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 26.8 | 59.8 | (34.1-97.1) |  | Male | 172 | 201.7 | 85.3 | (73.0-99.0) |
| Female | 18 | 27.5 | 65.6 | (38.8-103.6) |  | Female | 196 | 202.5 | 96.8 | (83.7-111.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

224

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 22 | 15.8 | 138.8 | (87.0-210.2) |  | Male | 8 | 10.4 | 77.2 | (33.2-152.0) |
| Female | 8 | 5.3 | 150.8 | (64.9-297.1) |  | Female | 9 | 8.1 | 111.5 | (50.9-211.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  | Male | 8 | 3.3 | 245.6 | (105.8-484.0) |
| Female | 1 | 2.6 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 5 | 9.3 | 53.7 | (17.3-125.4) |
| Female | 52 | 62.0 | 83.9 | (62.6-110.0) |  | Female | 7 | 7.6 | 91.9 | (36.8-189.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 7.5 | 133.4 | (63.9-245.3) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 17.4 | 69.0 | (35.6-120.5) |  |  |  |  |  |  |
| Female | 27 | 16.4 | 164.5 | (108.4-239.3) |  | Female | 6 | 5.5 | 109.3 | (39.9-237.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.2 | 118.9 | (38.3-277.4) |  | Male | 3 | 5.6 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 9 | 5.3 | 168.9 | (77.1-320.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 60 | 53.1 | 113.0 | (86.2-145.5) |
| Female | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 8.9 | 224.8 | (137.2-347.2) |  | Male | 1 | 3.8 | nc | (nc-nc) |
| Female | 3 | 4.8 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.5 | 92.2 | (33.7-200.8) |  | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 4 | 4.6 | nc | (nc-nc) |  | Female | 13 | 12.4 | 104.8 | (55.7-179.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 1.7 | nc | (nc-nc) |  | Female | 20 | 13.9 | 143.9 | (87.9-222.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 32 | 28.3 | 113.2 | (77.4-159.8) |  | Male | 223 | 210.0 | 106.2 | (92.7-121.1) |
| Female | 26 | 27.7 | 93.8 | (61.2-137.4) |  | Female | 220 | 207.2 | 106.2 | (92.6-121.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

225

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 13 | 14.2 | 91.7 | (48.8-156.8) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.6 | 108.8 | (35.1-253.9) |  |  |  |  |  |  |
| Female | 1 | 3.4 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 15.4 | 45.4 | (18.2-93.6) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 7.6 | nc | (nc-nc) |  | Male | 33 | 56.4 | 58.5 | (40.2-82.1) |
| Female | 4 | 6.5 | nc | (nc-nc) |  | Female | 38 | 46.1 | 82.5 | (58.4-113.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

226

# Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 16.8 | 59.4 | (28.5-109.3) |  | Male | 14 | 11.5 | 121.3 | (66.3-203.6) |
| Female | 8 | 6.3 | 127.4 | (54.9-251.1) |  | Female | 15 | 9.7 | 155.2 | (86.8-255.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 3.7 | 135.3 | (43.6-315.6) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 4 | 2.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 7 | 10.4 | 67.5 | (27.0-139.0) |
| Female | 68 | 75.9 | 89.6 | (69.5-113.5) |  | Female | 13 | 9.1 | 142.5 | (75.8-243.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 8 | 8.9 | 89.7 | (38.6-176.7) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 3 | 4.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 27 | 19.1 | 141.3 | (93.1-205.6) |  |  |  |  |  |  |
| Female | 28 | 19.5 | 143.7 | (95.5-207.7) |  | Female | 7 | 6.8 | 103.6 | (41.5-213.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.8 | 103.8 | (33.4-242.2) |  | Male | 9 | 6.2 | 146.3 | (66.8-277.7) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 11 | 6.4 | 173.1 | (86.3-309.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 60 | 63.0 | 95.3 | (72.7-122.6) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.3 | 126.7 | (67.4-216.6) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 10 | 5.8 | 172.8 | (82.7-317.7) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 7.2 | 83.3 | (30.4-181.2) |  | Male | 8 | 5.0 | 160.2 | (69.0-315.6) |
| Female | 6 | 5.3 | 112.4 | (41.0-244.6) |  | Female | 15 | 14.7 | 101.8 | (57.0-168.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 6.5 | 153.5 | (73.5-282.3) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 25 | 17.4 | 143.5 | (92.8-211.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 27 | 31.0 | 87.0 | (57.3-126.6) |  | Male | 239 | 237.7 | 100.6 | (88.2-114.1) |
| Female | 27 | 33.0 | 81.9 | (54.0-119.2) |  | Female | 271 | 249.8 | 108.5 | (96.0-122.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

227

# Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 12.9 | 85.6 | (42.7-153.1) |  | Male | 5 | 8.1 | 61.7 | (19.9-144.1) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 14 | 6.1 | 229.3 | (125.3-384.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.4 | 250.3 | (91.4-544.8) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 5 | 2.1 | 240.9 | (77.6-562.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 6 | 7.3 | 82.7 | (30.2-180.1) |
| Female | 45 | 50.0 | 90.1 | (65.7-120.5) |  | Female | 11 | 6.3 | 173.3 | (86.4-310.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 5.9 | 85.2 | (27.4-198.7) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 9 | 2.7 | 336.2 | (153.4-638.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 13.9 | 72.1 | (34.5-132.6) |  |  |  |  |  |  |
| Female | 8 | 13.8 | 57.9 | (24.9-114.1) |  | Female | 7 | 4.4 | 158.4 | (63.5-326.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 6 | 4.7 | 127.7 | (46.6-278.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 40 | 43.3 | 92.3 | (65.9-125.7) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 6.9 | 86.7 | (31.7-188.8) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 5 | 4.0 | 126.2 | (40.7-294.4) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.1 | nc | (nc-nc) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 3 | 8.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.4 | 114.1 | (36.8-266.2) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 15 | 11.5 | 130.3 | (72.9-214.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 23.0 | 56.5 | (30.1-96.6) |  | Male | 137 | 167.1 | 82.0 | (68.8-96.9) |
| Female | 15 | 24.5 | 61.3 | (34.3-101.1) |  | Female | 172 | 168.9 | 101.8 | (87.2-118.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

228

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 34.0 | 41.1 | (22.5-69.0) |  | Male | 33 | 21.5 | 153.5 | (105.7-215.6) |
| Female | 13 | 12.3 | 105.4 | (56.0-180.2) |  | Female | 25 | 16.4 | 152.4 | (98.6-225.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 6.3 | 159.6 | (76.4-293.5) |  | Male | 8 | 6.8 | 117.2 | (50.5-231.0) |
| Female | 7 | 5.1 | 137.8 | (55.2-283.9) |  | Female | 5 | 5.4 | 92.1 | (29.7-215.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 22 | 19.1 | 115.5 | (72.3-174.8) |
| Female | 133 | 125.9 | 105.6 | (88.4-125.2) |  | Female | 17 | 16.7 | 102.1 | (59.4-163.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 14.6 | 82.1 | (42.4-143.4) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 6 | 6.9 | 87.1 | (31.8-189.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 48 | 35.7 | 134.3 | (99.0-178.1) |  |  |  |  |  |  |
| Female | 49 | 37.4 | 131.2 | (97.0-173.4) |  | Female | 15 | 11.3 | 132.2 | (73.9-218.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 8.6 | 115.6 | (55.4-212.6) |  | Male | 18 | 11.6 | 154.9 | (91.8-244.8) |
| Female | 3 | 2.4 | nc | (nc-nc) |  | Female | 21 | 12.5 | 168.1 | (104.0-257.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 93 | 104.5 | 89.0 | (71.8-109.0) |
| Female | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 17.6 | 85.0 | (47.5-140.2) |  | Male | 9 | 7.8 | 114.9 | (52.4-218.1) |
| Female | 15 | 10.2 | 146.4 | (81.9-241.4) |  | Female | 7 | 4.8 | 144.5 | (57.9-297.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 5.0 | 159.3 | (68.6-313.9) |  | Male | 6 | 4.5 | 134.8 | (49.2-293.3) |
| Female | 4 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 13 | 13.4 | 97.2 | (51.7-166.2) |  | Male | 14 | 7.9 | 177.4 | (96.9-297.6) |
| Female | 11 | 9.9 | 111.1 | (55.4-198.8) |  | Female | 29 | 22.5 | 128.9 | (86.3-185.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 11.1 | 134.8 | (75.4-222.4) |  |  |  |  |  |  |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 32 | 27.8 | 115.1 | (78.7-162.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 62 | 60.5 | 102.4 | (78.5-131.3) |  | Male | 460 | 429.0 | 107.2 | (97.7-117.5) |
| Female | 83 | 63.3 | 131.2 | (104.5-162.6) |  | Female | 517 | 439.1 | 117.7 | (107.8-128.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

229

# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 6.9 | 115.8 | (49.9-228.3) |  | Male | 10 | 4.3 | 233.9 | (112.0-430.2) |
| Female | 0 | 2.4 | nc | (nc-nc) |  | Female | 2 | 2.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 26 | 21.8 | 119.5 | (78.0-175.1) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 6.9 | 115.3 | (49.6-227.2) |  |  |  |  |  |  |
| Female | 6 | 7.1 | 84.1 | (30.7-183.0) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 6 | 2.3 | 256.9 | (93.8-559.3) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 16 | 20.7 | 77.4 | (44.2-125.6) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 3 | 3.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 8 | 4.9 | 163.5 | (70.4-322.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 12.5 | 64.1 | (27.6-126.4) |  | Male | 80 | 84.8 | 94.3 | (74.8-117.4) |
| Female | 15 | 11.4 | 131.4 | (73.5-216.7) |  | Female | 84 | 78.5 | 107.1 | (85.4-132.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

230

# Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 6 | 8.0 | 75.2 | (27.5-163.7) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 11 | 8.1 | 135.1 | (67.3-241.7) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 2 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 26 | 30.0 | 86.5 | (56.5-126.8) |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 23 | 25.2 | 91.1 | (57.8-136.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

231

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 9.3 | 53.6 | (17.3-125.0) |  | Male | 2 | 6.0 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 1.8 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 4 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 8 | 5.3 | 150.6 | (64.8-296.8) |
| Female | 33 | 33.9 | 97.5 | (67.1-136.9) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 9.8 | 51.0 | (16.4-118.9) |  |  |  |  |  |  |
| Female | 4 | 9.2 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.5 | nc | (nc-nc) |  | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 29 | 31.1 | 93.3 | (62.5-134.1) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.1 | 99.0 | (31.9-231.0) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 2.4 | nc | (nc-nc) |  | Female | 4 | 6.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 12 | 7.7 | 154.9 | (80.0-270.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 17.1 | 99.4 | (57.9-159.2) |  | Male | 105 | 121.9 | 86.1 | (70.5-104.3) |
| Female | 13 | 16.4 | 79.3 | (42.2-135.6) |  | Female | 100 | 114.3 | 87.5 | (71.2-106.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

232

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 15.7 | 89.0 | (48.6-149.3) |  | Male | 19 | 8.7 | 218.4 | (131.4-341.1) |
| Female | 7 | 5.2 | 133.5 | (53.5-275.1) |  | Female | 10 | 5.6 | 178.9 | (85.6-329.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 3 | 2.9 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 10 | 7.5 | 132.7 | (63.5-244.1) |
| Female | 67 | 46.6 | 143.8 | (111.5-182.7) |  | Female | 6 | 6.6 | 91.1 | (33.3-198.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 5.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 14.4 | 90.0 | (47.9-153.9) |  |  |  |  |  |  |
| Female | 15 | 14.4 | 104.4 | (58.4-172.2) |  | Female | 3 | 4.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.8 | nc | (nc-nc) |  | Male | 4 | 5.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 7 | 5.2 | 135.2 | (54.2-278.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 29 | 47.3 | 61.3 | (41.1-88.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 6.8 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 2 | 4.1 | nc | (nc-nc) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.2 | 133.5 | (53.5-275.1) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 13 | 11.3 | 114.9 | (61.1-196.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 28.3 | 42.5 | (21.9-74.2) |  | Male | 144 | 181.2 | 79.5 | (67.0-93.6) |
| Female | 18 | 28.0 | 64.4 | (38.1-101.8) |  | Female | 183 | 168.0 | 108.9 | (93.7-125.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

233

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 13 | 7.4 | 176.5 | (93.9-301.9) |  | Female | 3 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 9 | 9.6 | 94.1 | (42.9-178.6) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 5.2 | 154.2 | (66.4-303.9) |  | Male | 30 | 35.8 | 83.9 | (56.6-119.8) |
| Female | 4 | 3.7 | nc | (nc-nc) |  | Female | 30 | 24.3 | 123.6 | (83.4-176.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

234

# Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 11.0 | 181.7 | (111.0-280.7) |  | Male | 12 | 7.9 | 151.7 | (78.3-265.0) |
| Female | 7 | 4.5 | 156.1 | (62.5-321.7) |  | Female | 6 | 7.0 | 85.3 | (31.2-185.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.7 | nc | (nc-nc) |  | Male | 5 | 2.4 | 207.4 | (66.8-484.0) |
| Female | 0 | 2.2 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 8 | 7.1 | 112.4 | (48.4-221.5) |
| Female | 60 | 54.9 | 109.3 | (83.4-140.7) |  | Female | 9 | 6.6 | 137.2 | (62.6-260.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 6.2 | 145.5 | (66.4-276.2) |
| Female | 0 | 2.0 | nc | (nc-nc) |  | Female | 4 | 2.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 13.2 | 60.8 | (26.2-119.9) |  |  |  |  |  |  |
| Female | 17 | 14.2 | 119.3 | (69.5-191.1) |  | Female | 6 | 4.8 | 124.4 | (45.4-270.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 47 | 42.1 | 111.7 | (82.1-148.6) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 7.2 | 83.3 | (30.4-181.2) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 5.0 | 201.3 | (96.4-370.3) |  | Male | 6 | 3.6 | 165.1 | (60.3-359.4) |
| Female | 7 | 3.9 | 181.6 | (72.8-374.3) |  | Female | 16 | 10.9 | 146.5 | (83.7-237.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 4.4 | 159.0 | (63.7-327.6) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 19 | 12.2 | 155.9 | (93.8-243.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 20.4 | 181.8 | (128.0-250.6) |  | Male | 200 | 160.6 | 124.6 | (107.9-143.1) |
| Female | 34 | 23.7 | 143.3 | (99.2-200.2) |  | Female | 222 | 180.0 | 123.3 | (107.6-140.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

235

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 11.9 | 150.6 | (89.2-238.1) |  | Male | 11 | 8.2 | 134.0 | (66.8-239.7) |
| Female | 9 | 5.6 | 161.8 | (73.8-307.1) |  | Female | 8 | 7.3 | 110.3 | (47.5-217.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 2.5 | 237.3 | (86.6-516.4) |  | Male | 0 | 2.6 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 7.3 | nc | (nc-nc) |
| Female | 58 | 56.4 | 102.8 | (78.0-132.9) |  | Female | 6 | 7.4 | 80.9 | (29.6-176.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 6.3 | 111.3 | (44.6-229.3) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 12 | 13.6 | 88.5 | (45.7-154.7) |  |  |  |  |  |  |
| Female | 14 | 16.6 | 84.4 | (46.1-141.6) |  | Female | 5 | 5.1 | 98.0 | (31.6-228.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 5 | 4.4 | 114.7 | (37.0-267.6) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 7 | 5.6 | 124.8 | (50.0-257.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 37 | 43.8 | 84.4 | (59.4-116.4) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 7.2 | 139.2 | (66.6-256.0) |  | Male | 6 | 2.9 | 205.9 | (75.2-448.3) |
| Female | 2 | 4.6 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 2.0 | 248.4 | (80.0-579.6) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 5.0 | 100.7 | (32.5-235.0) |  | Male | 1 | 3.4 | nc | (nc-nc) |
| Female | 6 | 4.4 | 136.7 | (49.9-297.6) |  | Female | 9 | 9.8 | 91.5 | (41.8-173.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.7 | 106.2 | (34.2-247.7) |  |  |  |  |  |  |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 12 | 12.6 | 95.2 | (49.1-166.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 33 | 22.1 | 149.0 | (102.6-209.3) |  | Male | 179 | 167.1 | 107.1 | (92.0-124.0) |
| Female | 16 | 28.1 | 56.9 | (32.5-92.4) |  | Female | 173 | 196.1 | 88.2 | (75.6-102.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

236

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 5.9 | nc | (nc-nc) |  | Male | 6 | 3.7 | 162.4 | (59.3-353.4) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 2 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 20 | 19.9 | 100.6 | (61.4-155.3) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 5.2 | 135.1 | (54.1-278.3) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 26 | 19.1 | 136.1 | (88.9-199.4) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 2 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 3 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 10.7 | 65.7 | (26.3-135.3) |  | Male | 75 | 75.5 | 99.3 | (78.1-124.5) |
| Female | 6 | 9.4 | 63.6 | (23.2-138.5) |  | Female | 61 | 66.8 | 91.4 | (69.9-117.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

237

# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 87 | 72.3 | 120.4 | (96.4-148.5) |  | Male | 38 | 43.0 | 88.4 | (62.6-121.4) |
| Female | 36 | 27.9 | 129.1 | (90.4-178.8) |  | Female | 33 | 34.4 | 96.1 | (66.1-134.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 11.7 | 85.2 | (40.8-156.6) |  | Male | 21 | 13.7 | 152.8 | (94.6-233.6) |
| Female | 14 | 10.3 | 135.3 | (73.9-227.0) |  | Female | 20 | 12.0 | 166.0 | (101.4-256.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 4 | 2.4 | nc | (nc-nc) |  | Male | 43 | 38.4 | 112.1 | (81.1-151.0) |
| Female | 276 | 262.2 | 105.3 | (93.2-118.5) |  | Female | 56 | 36.5 | 153.6 | (116.0-199.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 35 | 28.4 | 123.0 | (85.7-171.1) |
| Female | 12 | 8.3 | 145.4 | (75.0-254.0) |  | Female | 13 | 14.9 | 87.4 | (46.5-149.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 58 | 73.5 | 78.9 | (59.9-102.0) |  |  |  |  |  |  |
| Female | 90 | 84.5 | 106.5 | (85.6-130.9) |  | Female | 20 | 24.0 | 83.2 | (50.8-128.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 17.6 | 73.7 | (39.2-126.1) |  | Male | 22 | 24.3 | 90.4 | (56.7-136.9) |
| Female | 3 | 5.3 | nc | (nc-nc) |  | Female | 33 | 28.6 | 115.5 | (79.5-162.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 4.3 | 116.6 | (37.6-272.0) |  | Male | 252 | 211.4 | 119.2 | (104.9-134.9) |
| Female | 8 | 3.7 | 215.3 | (92.7-424.2) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 28 | 34.4 | 81.5 | (54.1-117.7) |  | Male | 15 | 16.2 | 92.6 | (51.8-152.7) |
| Female | 19 | 21.6 | 87.9 | (52.9-137.3) |  | Female | 8 | 11.1 | 72.2 | (31.1-142.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 16 | 10.0 | 160.7 | (91.8-260.9) |  | Male | 12 | 7.1 | 168.9 | (87.2-295.1) |
| Female | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 32 | 27.1 | 118.1 | (80.8-166.8) |  | Male | 15 | 14.3 | 105.0 | (58.7-173.1) |
| Female | 28 | 21.4 | 131.0 | (87.0-189.3) |  | Female | 43 | 43.5 | 98.9 | (71.6-133.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 23 | 21.8 | 105.4 | (66.8-158.2) |  |  |  |  |  |  |
| Female | 9 | 8.2 | 110.3 | (50.3-209.5) |  | Female | 55 | 57.9 | 95.0 | (71.6-123.7) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 122 | 124.3 | 98.1 | (81.5-117.2) |  | Male | 945 | 868.6 | 108.8 | (102.0-116.0) |
| Female | 161 | 136.5 | 117.9 | (100.4-137.6) |  | Female | 1031 | 938.7 | 109.8 | (103.2-116.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

238

# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 7.6 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 3.5 | nc | (nc-nc) |  | Male | 12 | 25.8 | 46.4 | (24.0-81.1) |
| Female | 0 | 3.7 | nc | (nc-nc) |  | Female | 10 | 25.3 | 39.6 | (18.9-72.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

239

# Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 16.2 | 129.5 | (80.1-197.9) |  | Male | 12 | 11.1 | 108.1 | (55.8-188.8) |
| Female | 8 | 5.4 | 148.6 | (64.0-292.8) |  | Female | 13 | 9.0 | 143.7 | (76.5-245.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.5 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) |  | Female | 1 | 2.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 13 | 9.9 | 130.7 | (69.5-223.6) |
| Female | 89 | 72.8 | 122.2 | (98.1-150.3) |  | Female | 8 | 8.3 | 96.9 | (41.7-190.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 8.5 | 129.6 | (64.6-232.0) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 18.6 | 140.1 | (91.5-205.3) |  |  |  |  |  |  |
| Female | 24 | 16.9 | 141.9 | (90.9-211.1) |  | Female | 4 | 6.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 4.6 | 109.7 | (35.4-256.1) |  | Male | 4 | 5.9 | nc | (nc-nc) |
| Female | 1 | 1.1 | nc | (nc-nc) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 68 | 59.4 | 114.6 | (89.0-145.2) |
| Female | 2 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 9.9 | 131.8 | (70.1-225.3) |  | Male | 5 | 4.0 | 126.5 | (40.8-295.1) |
| Female | 7 | 5.4 | 129.4 | (51.9-266.7) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 6.9 | 130.0 | (59.3-246.9) |  | Male | 6 | 4.7 | 126.8 | (46.3-276.0) |
| Female | 6 | 4.8 | 125.7 | (45.9-273.7) |  | Female | 20 | 14.7 | 136.1 | (83.1-210.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 6.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 17 | 16.6 | 102.4 | (59.6-163.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 36 | 29.7 | 121.2 | (84.9-167.9) |  | Male | 260 | 226.8 | 114.6 | (101.1-129.4) |
| Female | 47 | 29.9 | 157.1 | (115.4-208.9) |  | Female | 276 | 231.1 | 119.4 | (105.7-134.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

240

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 10.5 | 47.4 | (15.3-110.7) |  | Male | 8 | 7.5 | 107.1 | (46.1-211.0) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 3 | 5.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 7 | 6.7 | 103.7 | (41.5-213.7) |
| Female | 52 | 47.6 | 109.2 | (81.5-143.2) |  | Female | 5 | 5.2 | 95.5 | (30.8-222.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 6.2 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 12.5 | 87.9 | (43.8-157.4) |  |  |  |  |  |  |
| Female | 16 | 10.5 | 152.7 | (87.2-248.0) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.2 | nc | (nc-nc) |  | Male | 5 | 4.0 | 125.1 | (40.3-291.9) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 31 | 43.6 | 71.1 | (48.3-100.9) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 6.9 | 72.1 | (23.2-168.1) |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 5 | 3.5 | 142.6 | (45.9-332.7) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 4.6 | 109.8 | (35.4-256.2) |  | Male | 7 | 3.4 | 208.3 | (83.4-429.1) |
| Female | 4 | 2.9 | nc | (nc-nc) |  | Female | 7 | 9.4 | 74.7 | (29.9-153.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 4.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 15 | 11.1 | 135.2 | (75.6-223.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 22 | 19.7 | 111.5 | (69.8-168.8) |  | Male | 141 | 156.8 | 89.9 | (75.7-106.1) |
| Female | 19 | 19.5 | 97.5 | (58.7-152.3) |  | Female | 156 | 148.6 | 105.0 | (89.1-122.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

241

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 3.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 11 | 10.2 | 108.2 | (53.9-193.6) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 3 | 9.7 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

242

# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 6 | 7.1 | 84.3 | (30.8-183.6) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 5.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 13 | 21.0 | 61.9 | (32.9-105.9) |
| Female | 0 | 3.7 | nc | (nc-nc) |  | Female | 14 | 25.2 | 55.5 | (30.3-93.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

243

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 3 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 5 | 6.8 | 73.3 | (23.6-171.0) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 6 | 6.3 | 95.9 | (35.0-208.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  | Male | 17 | 23.3 | 73.0 | (42.5-116.9) |
| Female | 3 | 2.6 | nc | (nc-nc) |  | Female | 19 | 21.0 | 90.6 | (54.5-141.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

244

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 62 | 54.6 | 113.5 | (87.0-145.5) |  | Male | 31 | 33.8 | 91.8 | (62.3-130.3) |
| Female | 26 | 22.3 | 116.8 | (76.3-171.1) |  | Female | 28 | 28.6 | 97.9 | (65.0-141.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 14 | 9.6 | 145.4 | (79.4-244.0) |  | Male | 9 | 10.7 | 83.8 | (38.2-159.0) |
| Female | 7 | 8.8 | 79.5 | (31.9-163.8) |  | Female | 3 | 9.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 34 | 30.1 | 112.8 | (78.1-157.6) |
| Female | 201 | 222.6 | 90.3 | (78.2-103.7) |  | Female | 31 | 29.8 | 104.1 | (70.7-147.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 33 | 23.7 | 139.1 | (95.7-195.3) |
| Female | 9 | 7.0 | 128.1 | (58.5-243.2) |  | Female | 10 | 12.4 | 80.9 | (38.7-148.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 55 | 57.3 | 96.1 | (72.4-125.0) |  |  |  |  |  |  |
| Female | 79 | 66.0 | 119.8 | (94.8-149.3) |  | Female | 13 | 20.2 | 64.3 | (34.2-110.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 26 | 14.1 | 184.2 | (120.3-270.0) |  | Male | 20 | 19.0 | 105.5 | (64.4-162.9) |
| Female | 5 | 4.3 | 117.5 | (37.9-274.2) |  | Female | 13 | 22.4 | 58.0 | (30.8-99.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 3.6 | nc | (nc-nc) |  | Male | 163 | 178.6 | 91.3 | (77.8-106.4) |
| Female | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 29 | 28.1 | 103.0 | (69.0-148.0) |  | Male | 8 | 12.6 | 63.6 | (27.4-125.4) |
| Female | 19 | 18.2 | 104.1 | (62.7-162.6) |  | Female | 9 | 8.6 | 105.2 | (48.0-199.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 8 | 8.2 | 98.2 | (42.3-193.4) |  | Male | 8 | 6.2 | 128.1 | (55.2-252.4) |
| Female | 3 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 21.0 | 85.7 | (50.7-135.4) |  | Male | 15 | 12.1 | 123.5 | (69.1-203.8) |
| Female | 8 | 17.3 | 46.1 | (19.9-90.9) |  | Female | 32 | 37.6 | 85.2 | (58.3-120.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 17 | 18.1 | 94.0 | (54.7-150.5) |  |  |  |  |  |  |
| Female | 6 | 6.8 | 88.0 | (32.1-191.6) |  | Female | 52 | 51.0 | 101.9 | (76.1-133.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 112 | 96.3 | 116.3 | (95.8-139.9) |  | Male | 723 | 694.8 | 104.1 | (96.6-111.9) |
| Female | 143 | 114.3 | 125.1 | (105.4-147.4) |  | Female | 757 | 779.5 | 97.1 | (90.3-104.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

245

# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 4 | 3.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.1 | nc | (nc-nc) |  | Male | 12 | 14.8 | 81.2 | (41.9-141.9) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 10 | 12.1 | 82.4 | (39.4-151.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

246

# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 13 | 7.1 | 182.4 | (97.0-311.9) |  | Male | 5 | 5.0 | 100.2 | (32.3-233.7) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 8 | 4.5 | 178.2 | (76.7-351.1) |
| Female | 39 | 34.8 | 112.0 | (79.7-153.2) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 4 | 1.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 8.3 | 83.9 | (33.6-172.8) |  |  |  |  |  |  |
| Female | 12 | 9.4 | 127.5 | (65.8-222.8) |  | Female | 6 | 3.1 | 194.0 | (70.9-422.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 7 | 2.6 | 265.7 | (106.4-547.5) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 31 | 27.3 | 113.6 | (77.2-161.3) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 10 | 4.5 | 222.5 | (106.5-409.1) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 7 | 2.5 | 276.8 | (110.9-570.3) |  | Female | 8 | 6.9 | 116.3 | (50.1-229.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 7.8 | 76.9 | (28.1-167.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 15 | 13.0 | 115.4 | (64.5-190.3) |  | Male | 130 | 102.5 | 126.9 | (106.0-150.7) |
| Female | 22 | 15.6 | 140.8 | (88.2-213.3) |  | Female | 134 | 116.5 | 115.0 | (96.4-136.2) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

247

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 71 | 65.2 | 108.9 | (85.0-137.3) |  | Male | 65 | 42.6 | 152.5 | (117.7-194.4) |
| Female | 19 | 22.9 | 82.8 | (49.8-129.3) |  | Female | 61 | 32.3 | 188.6 | (144.2-242.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 12.7 | 86.7 | (43.2-155.1) |  | Male | 9 | 13.4 | 67.1 | (30.6-127.3) |
| Female | 10 | 10.1 | 98.9 | (47.3-181.8) |  | Female | 9 | 10.5 | 86.0 | (39.2-163.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 49 | 37.9 | 129.2 | (95.6-170.9) |
| Female | 300 | 259.9 | 115.4 | (102.7-129.3) |  | Female | 35 | 32.2 | 108.8 | (75.8-151.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 37 | 31.5 | 117.4 | (82.6-161.8) |
| Female | 5 | 8.6 | 57.9 | (18.7-135.2) |  | Female | 14 | 13.8 | 101.7 | (55.6-170.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 79 | 70.5 | 112.0 | (88.7-139.6) |  |  |  |  |  |  |
| Female | 74 | 68.7 | 107.6 | (84.5-135.1) |  | Female | 31 | 23.0 | 134.6 | (91.4-191.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 21 | 18.0 | 116.8 | (72.2-178.5) |  | Male | 26 | 23.4 | 111.1 | (72.6-162.8) |
| Female | 1 | 4.5 | nc | (nc-nc) |  | Female | 21 | 23.0 | 91.2 | (56.4-139.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 4.9 | nc | (nc-nc) |  | Male | 248 | 238.6 | 103.9 | (91.4-117.7) |
| Female | 2 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 33 | 37.3 | 88.5 | (60.9-124.3) |  | Male | 10 | 15.4 | 64.9 | (31.1-119.3) |
| Female | 19 | 20.4 | 93.0 | (55.9-145.2) |  | Female | 9 | 8.8 | 102.0 | (46.5-193.6) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 13 | 10.6 | 123.1 | (65.5-210.5) |  | Male | 5 | 8.8 | 57.1 | (18.4-133.2) |
| Female | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 37 | 26.1 | 141.9 | (99.9-195.6) |  | Male | 19 | 16.9 | 112.6 | (67.8-175.8) |
| Female | 17 | 18.5 | 91.8 | (53.4-146.9) |  | Female | 70 | 46.2 | 151.6 | (118.2-191.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 27 | 23.3 | 115.8 | (76.3-168.5) |  |  |  |  |  |  |
| Female | 5 | 7.4 | 67.9 | (21.9-158.4) |  | Female | 70 | 60.3 | 116.0 | (90.4-146.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 130 | 119.5 | 108.8 | (90.9-129.2) |  | Male | 975 | 884.6 | 110.2 | (103.4-117.4) |
| Female | 135 | 121.9 | 110.7 | (92.8-131.1) |  | Female | 978 | 868.4 | 112.6 | (105.7-119.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

248

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 11 | 12.2 | 90.0 | (44.9-161.0) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 2 | 0.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 13 | 12.9 | 100.4 | (53.4-171.7) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.2 | nc | (nc-nc) |  | Male | 38 | 46.1 | 82.4 | (58.3-113.2) |
| Female | 6 | 5.4 | 111.8 | (40.8-243.4) |  | Female | 43 | 39.0 | 110.2 | (79.8-148.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

249

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 3.3 | 150.3 | (48.4-350.8) |  | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 3 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 16 | 14.6 | 109.9 | (62.8-178.5) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 2.0 | 300.5 | (109.7-654.1) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 4.0 | 125.2 | (40.3-292.1) |  |  |  |  |  |  |
| Female | 2 | 3.1 | nc | (nc-nc) |  | Female | 5 | 1.2 | 403.5 | (130.0-941.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 20 | 14.4 | 138.9 | (84.8-214.6) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 2.2 | 224.6 | (72.4-524.2) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 5 | 1.1 | 473.1 | (152.5-1104.0) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 2.7 | 183.3 | (59.1-427.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 2 | 3.6 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 6.2 | nc | (nc-nc) |  | Male | 67 | 50.3 | 133.3 | (103.3-169.3) |
| Female | 3 | 5.6 | nc | (nc-nc) |  | Female | 51 | 44.7 | 114.0 | (84.9-149.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

250

# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 4.9 | nc | (nc-nc) |  | Male | 7 | 3.3 | 214.1 | (85.8-441.1) |
| Female | 4 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 2.9 | nc | (nc-nc) |
| Female | 19 | 16.3 | 116.4 | (70.1-181.8) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 2.7 | 223.7 | (81.7-486.9) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 5.7 | 123.2 | (49.3-253.8) |  |  |  |  |  |  |
| Female | 8 | 4.7 | 169.0 | (72.7-332.9) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 14 | 19.6 | 71.5 | (39.0-119.9) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 2 | 2.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 12 | 9.1 | 132.0 | (68.1-230.7) |  | Male | 79 | 69.3 | 113.9 | (90.2-142.0) |
| Female | 14 | 8.3 | 168.7 | (92.2-283.1) |  | Female | 72 | 56.5 | 127.4 | (99.7-160.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

251

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 91 | 97.3 | 93.5 | (75.3-114.8) |  | Male | 51 | 62.8 | 81.2 | (60.4-106.7) |
| Female | 31 | 36.7 | 84.6 | (57.5-120.0) |  | Female | 56 | 52.6 | 106.5 | (80.4-138.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 18 | 18.8 | 95.6 | (56.6-151.1) |  | Male | 18 | 19.4 | 92.6 | (54.8-146.3) |
| Female | 14 | 15.9 | 88.0 | (48.1-147.7) |  | Female | 11 | 16.4 | 67.0 | (33.4-120.0) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 3.3 | nc | (nc-nc) |  | Male | 49 | 56.0 | 87.5 | (64.7-115.7) |
| Female | 379 | 394.1 | 96.2 | (86.7-106.4) |  | Female | 60 | 50.9 | 117.9 | (89.9-151.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 66 | 43.4 | 152.1 | (117.6-193.5) |
| Female | 19 | 13.9 | 136.8 | (82.3-213.6) |  | Female | 22 | 21.3 | 103.4 | (64.8-156.6) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 145 | 103.9 | 139.6 | (117.8-164.2) |  |  |  |  |  |  |
| Female | 108 | 110.9 | 97.4 | (79.9-117.6) |  | Female | 32 | 35.6 | 89.8 | (61.4-126.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 28 | 25.0 | 112.0 | (74.4-161.9) |  | Male | 30 | 33.7 | 88.9 | (60.0-127.0) |
| Female | 11 | 7.0 | 156.1 | (77.8-279.3) |  | Female | 36 | 36.8 | 97.9 | (68.5-135.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 8 | 8.2 | 97.6 | (42.0-192.3) |  | Male | 265 | 309.3 | 85.7 | (75.7-96.7) |
| Female | 8 | 6.7 | 118.8 | (51.2-234.1) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 47 | 52.0 | 90.4 | (66.4-120.2) |  | Male | 25 | 22.7 | 110.0 | (71.2-162.5) |
| Female | 36 | 31.7 | 113.6 | (79.5-157.3) |  | Female | 11 | 14.3 | 77.1 | (38.4-138.0) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 19 | 14.6 | 130.1 | (78.3-203.2) |  | Male | 15 | 16.5 | 90.7 | (50.7-149.6) |
| Female | 6 | 4.8 | 125.5 | (45.8-273.2) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 23 | 39.1 | 58.8 | (37.3-88.3) |  | Male | 18 | 24.6 | 73.0 | (43.3-115.4) |
| Female | 27 | 29.9 | 90.4 | (59.5-131.5) |  | Female | 69 | 76.8 | 89.9 | (69.9-113.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 63 | 32.3 | 195.0 | (149.8-249.4) |  |  |  |  |  |  |
| Female | 14 | 11.4 | 122.5 | (66.9-205.6) |  | Female | 89 | 88.7 | 100.4 | (80.6-123.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 233 | 171.8 | 135.6 | (118.8-154.2) |  | Male | 1318 | 1255.8 | 105.0 | (99.4-110.8) |
| Female | 230 | 191.4 | 120.2 | (105.1-136.8) |  | Female | 1374 | 1358.0 | 101.2 | (95.9-106.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

252

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 34.2 | 102.2 | (71.2-142.2) |  | Male | 17 | 21.9 | 77.6 | (45.2-124.2) |
| Female | 7 | 12.7 | 55.1 | (22.1-113.5) |  | Female | 16 | 18.6 | 86.3 | (49.3-140.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.5 | 92.8 | (33.9-201.9) |  | Male | 7 | 6.9 | 101.3 | (40.6-208.7) |
| Female | 4 | 5.8 | nc | (nc-nc) |  | Female | 10 | 5.8 | 173.1 | (82.9-318.4) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 15 | 19.6 | 76.7 | (42.9-126.5) |
| Female | 123 | 144.6 | 85.0 | (70.7-101.5) |  | Female | 16 | 18.1 | 88.4 | (50.5-143.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 15.3 | 39.1 | (14.3-85.1) |
| Female | 7 | 5.0 | 138.8 | (55.6-285.9) |  | Female | 8 | 7.7 | 104.4 | (44.9-205.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 39 | 36.7 | 106.3 | (75.6-145.4) |  |  |  |  |  |  |
| Female | 42 | 39.0 | 107.6 | (77.5-145.4) |  | Female | 11 | 12.8 | 86.0 | (42.9-153.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 8.9 | 67.7 | (24.7-147.4) |  | Male | 11 | 11.8 | 93.1 | (46.4-166.6) |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 8 | 12.8 | 62.5 | (26.9-123.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.6 | nc | (nc-nc) |  | Male | 118 | 109.5 | 107.8 | (89.2-129.1) |
| Female | 0 | 2.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 21 | 18.3 | 114.6 | (70.9-175.2) |  | Male | 8 | 8.0 | 100.0 | (43.1-197.0) |
| Female | 11 | 11.3 | 97.1 | (48.4-173.8) |  | Female | 7 | 5.0 | 139.8 | (56.0-288.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 5.2 | 115.5 | (42.2-251.4) |  | Male | 0 | 4.8 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 13.6 | 73.7 | (35.3-135.6) |  | Male | 9 | 8.4 | 107.3 | (49.0-203.8) |
| Female | 3 | 10.6 | nc | (nc-nc) |  | Female | 33 | 27.4 | 120.5 | (82.9-169.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 16 | 11.6 | 138.3 | (79.0-224.6) |  |  |  |  |  |  |
| Female | 3 | 4.1 | nc | (nc-nc) |  | Female | 29 | 32.6 | 88.8 | (59.5-127.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 46 | 60.7 | 75.8 | (55.5-101.1) |  | Male | 401 | 441.0 | 90.9 | (82.2-100.3) |
| Female | 56 | 66.9 | 83.7 | (63.2-108.7) |  | Female | 428 | 486.2 | 88.0 | (79.9-96.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

253

# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 16 | 13.7 | 116.6 | (66.6-189.4) |  | Male | 4 | 9.1 | nc | (nc-nc) |
| Female | 7 | 5.1 | 137.7 | (55.2-283.8) |  | Female | 9 | 7.2 | 124.4 | (56.7-236.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 2.8 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) |  | Female | 4 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 9 | 8.1 | 111.2 | (50.7-211.1) |
| Female | 58 | 57.0 | 101.7 | (77.2-131.4) |  | Female | 8 | 7.2 | 111.6 | (48.1-220.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 6.8 | 73.9 | (23.8-172.4) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 24 | 15.3 | 156.4 | (100.2-232.7) |  |  |  |  |  |  |
| Female | 20 | 15.3 | 130.3 | (79.6-201.3) |  | Female | 5 | 5.0 | 99.2 | (32.0-231.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 7 | 4.9 | 142.2 | (57.0-292.9) |
| Female | 4 | 1.0 | nc | (nc-nc) |  | Female | 3 | 5.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 49 | 47.6 | 103.0 | (76.2-136.2) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 7.9 | 165.5 | (88.0-283.0) |  | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 10 | 4.5 | 222.4 | (106.5-409.0) |  | Female | 4 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 6 | 1.9 | 317.1 | (115.8-690.3) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 6 | 3.6 | 165.0 | (60.2-359.1) |
| Female | 5 | 4.1 | 120.6 | (38.9-281.4) |  | Female | 24 | 10.6 | 226.1 | (144.8-336.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 14 | 12.9 | 108.8 | (59.4-182.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 24.8 | 136.9 | (94.8-191.3) |  | Male | 214 | 185.1 | 115.6 | (100.6-132.2) |
| Female | 30 | 27.0 | 111.1 | (74.9-158.6) |  | Female | 235 | 192.1 | 122.3 | (107.2-139.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

254

# Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 36 | 26.0 | 138.4 | (96.9-191.7) |  | Male | 18 | 16.9 | 106.3 | (62.9-168.0) |
| Female | 6 | 10.5 | 57.3 | (20.9-124.7) |  | Female | 13 | 14.2 | 91.3 | (48.5-156.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 5.2 | 96.7 | (31.1-225.6) |  | Male | 5 | 5.3 | 93.9 | (30.3-219.1) |
| Female | 6 | 4.5 | 133.7 | (48.8-291.0) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 18 | 15.1 | 119.2 | (70.6-188.4) |
| Female | 135 | 111.9 | 120.7 | (101.2-142.9) |  | Female | 8 | 14.3 | 55.8 | (24.0-109.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 12.3 | 57.1 | (22.9-117.6) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 5 | 6.0 | 83.0 | (26.8-193.8) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 28 | 28.1 | 99.7 | (66.2-144.1) |  |  |  |  |  |  |
| Female | 22 | 31.5 | 69.8 | (43.7-105.7) |  | Female | 10 | 10.0 | 100.3 | (48.0-184.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 10 | 7.0 | 143.4 | (68.7-263.8) |  | Male | 7 | 9.2 | 75.9 | (30.4-156.5) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 9 | 10.6 | 85.1 | (38.8-161.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.9 | nc | (nc-nc) |  | Male | 56 | 88.3 | 63.4 | (47.9-82.4) |
| Female | 4 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 14.5 | 89.7 | (47.7-153.4) |  | Male | 6 | 6.1 | 98.0 | (35.8-213.3) |
| Female | 6 | 8.9 | 67.5 | (24.6-146.9) |  | Female | 1 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.1 | nc | (nc-nc) |  | Male | 6 | 3.4 | 174.6 | (63.8-380.0) |
| Female | 0 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 11 | 10.6 | 103.8 | (51.8-185.8) |  | Male | 8 | 6.6 | 120.7 | (52.0-237.8) |
| Female | 11 | 8.4 | 130.5 | (65.0-233.4) |  | Female | 28 | 20.0 | 140.2 | (93.2-202.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 9.1 | 98.8 | (45.1-187.5) |  |  |  |  |  |  |
| Female | 5 | 3.3 | 153.8 | (49.6-358.9) |  | Female | 28 | 25.1 | 111.4 | (74.0-161.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 42 | 46.9 | 89.5 | (64.5-121.0) |  | Male | 311 | 344.4 | 90.3 | (80.6-100.9) |
| Female | 47 | 54.0 | 87.1 | (64.0-115.8) |  | Female | 395 | 382.0 | 103.4 | (93.4-114.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

255

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 12.5 | 80.0 | (38.3-147.1) |  | Male | 10 | 8.4 | 118.8 | (56.9-218.5) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 4 | 5.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 7 | 7.6 | 92.1 | (36.9-189.7) |
| Female | 57 | 47.0 | 121.3 | (91.9-157.2) |  | Female | 7 | 5.4 | 130.0 | (52.1-267.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 6.7 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 14.2 | 91.4 | (48.6-156.3) |  |  |  |  |  |  |
| Female | 12 | 10.9 | 109.7 | (56.6-191.6) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 3.6 | nc | (nc-nc) |  | Male | 1 | 4.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 39 | 49.2 | 79.3 | (56.4-108.5) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 7.7 | 104.2 | (44.9-205.4) |  | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 6 | 3.5 | 172.0 | (62.8-374.3) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 3 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 5.2 | nc | (nc-nc) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 8 | 9.1 | 87.8 | (37.8-173.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.2 | nc | (nc-nc) |  | Female | 16 | 11.0 | 146.0 | (83.4-237.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 22.8 | 114.0 | (74.4-167.0) |  | Male | 139 | 177.6 | 78.3 | (65.8-92.4) |
| Female | 19 | 19.6 | 96.9 | (58.3-151.4) |  | Female | 161 | 149.5 | 107.7 | (91.7-125.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

256

# Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 50 | 47.8 | 104.6 | (77.7-138.0) |  | Male | 23 | 32.5 | 70.8 | (44.8-106.2) |
| Female | 16 | 19.7 | 81.2 | (46.4-131.8) |  | Female | 27 | 28.3 | 95.5 | (62.9-139.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 11 | 10.3 | 106.7 | (53.2-190.9) |  | Male | 6 | 9.8 | 61.2 | (22.3-133.2) |
| Female | 11 | 8.6 | 127.9 | (63.8-228.8) |  | Female | 11 | 8.8 | 125.0 | (62.3-223.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 31 | 29.0 | 106.9 | (72.7-151.8) |
| Female | 208 | 213.8 | 97.3 | (84.5-111.4) |  | Female | 27 | 27.5 | 98.3 | (64.7-143.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 22 | 23.1 | 95.3 | (59.7-144.2) |
| Female | 3 | 7.5 | nc | (nc-nc) |  | Female | 16 | 11.4 | 139.8 | (79.9-227.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 67 | 53.3 | 125.7 | (97.4-159.6) |  |  |  |  |  |  |
| Female | 45 | 59.8 | 75.3 | (54.9-100.8) |  | Female | 17 | 19.1 | 89.0 | (51.8-142.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 12.6 | 87.1 | (43.4-155.9) |  | Male | 23 | 16.9 | 135.8 | (86.1-203.8) |
| Female | 5 | 3.8 | 130.9 | (42.2-305.6) |  | Female | 17 | 19.9 | 85.6 | (49.8-137.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 4.7 | 107.2 | (34.5-250.2) |  | Male | 116 | 158.0 | 73.4 | (60.6-88.0) |
| Female | 4 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 35 | 27.4 | 127.6 | (88.8-177.4) |  | Male | 20 | 11.5 | 174.5 | (106.6-269.5) |
| Female | 32 | 17.1 | 187.2 | (128.0-264.2) |  | Female | 8 | 7.7 | 103.9 | (44.7-204.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 10 | 7.4 | 134.8 | (64.5-247.9) |  | Male | 7 | 9.5 | 73.9 | (29.6-152.3) |
| Female | 9 | 2.5 | 353.9 | (161.5-671.9) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 31 | 20.3 | 152.7 | (103.7-216.8) |  | Male | 11 | 13.9 | 79.4 | (39.6-142.1) |
| Female | 11 | 16.2 | 68.0 | (33.9-121.7) |  | Female | 44 | 41.2 | 106.9 | (77.7-143.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 27 | 16.9 | 160.0 | (105.4-232.8) |  |  |  |  |  |  |
| Female | 6 | 6.2 | 96.9 | (35.4-210.9) |  | Female | 35 | 47.7 | 73.3 | (51.1-102.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 127 | 85.0 | 149.4 | (124.6-177.8) |  | Male | 683 | 642.7 | 106.3 | (98.5-114.6) |
| Female | 139 | 103.2 | 134.7 | (113.2-159.0) |  | Female | 742 | 733.0 | 101.2 | (94.1-108.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

257

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 3.0 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 5 | 9.4 | 53.3 | (17.2-124.5) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 2.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 13 | 9.6 | 135.6 | (72.1-231.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 1.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 27 | 36.0 | 75.1 | (49.4-109.2) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 17 | 32.1 | 52.9 | (30.8-84.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

258

# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 6.0 | nc | (nc-nc) |  | Male | 5 | 3.9 | 127.6 | (41.1-297.8) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 4 | 3.5 | nc | (nc-nc) |
| Female | 24 | 24.0 | 100.1 | (64.1-148.9) |  | Female | 3 | 3.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 6.5 | 107.9 | (43.2-222.4) |  |  |  |  |  |  |
| Female | 8 | 6.4 | 124.5 | (53.6-245.4) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 23 | 22.6 | 101.9 | (64.6-152.9) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 13 | 11.0 | 117.7 | (62.6-201.3) |  | Male | 78 | 82.4 | 94.7 | (74.8-118.2) |
| Female | 3 | 10.7 | nc | (nc-nc) |  | Female | 65 | 80.2 | 81.1 | (62.6-103.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

259

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 17.6 | 119.0 | (73.6-181.9) |  | Male | 15 | 11.8 | 127.1 | (71.1-209.7) |
| Female | 11 | 7.2 | 152.7 | (76.1-273.2) |  | Female | 17 | 10.0 | 169.3 | (98.5-271.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 3.6 | 164.9 | (60.2-359.0) |  | Male | 3 | 3.6 | nc | (nc-nc) |
| Female | 3 | 3.1 | nc | (nc-nc) |  | Female | 0 | 3.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 12 | 10.5 | 114.4 | (59.1-199.9) |
| Female | 81 | 79.5 | 101.9 | (81.0-126.7) |  | Female | 16 | 10.1 | 158.6 | (90.6-257.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 8.8 | 136.1 | (70.3-237.8) |
| Female | 1 | 2.7 | nc | (nc-nc) |  | Female | 4 | 4.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 25 | 19.5 | 128.2 | (82.9-189.2) |  |  |  |  |  |  |
| Female | 25 | 21.5 | 116.4 | (75.3-171.9) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 6 | 4.9 | 122.6 | (44.8-266.9) |  | Male | 8 | 6.4 | 125.2 | (53.9-246.7) |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 7 | 7.2 | 96.8 | (38.8-199.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 71 | 65.3 | 108.7 | (84.9-137.1) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 10.3 | 126.0 | (67.0-215.5) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 16 | 6.3 | 252.1 | (144.0-409.4) |  | Female | 7 | 2.7 | 255.3 | (102.3-526.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.9 | nc | (nc-nc) |  | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 7.2 | 194.3 | (106.1-326.1) |  | Male | 4 | 4.8 | nc | (nc-nc) |
| Female | 12 | 5.8 | 206.5 | (106.6-360.7) |  | Female | 22 | 14.3 | 154.0 | (96.5-233.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 6.5 | 76.6 | (24.7-178.8) |  |  |  |  |  |  |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 24 | 18.4 | 130.8 | (83.8-194.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 34 | 32.4 | 104.9 | (72.6-146.6) |  | Male | 282 | 243.6 | 115.8 | (102.6-130.1) |
| Female | 48 | 38.5 | 124.8 | (92.0-165.4) |  | Female | 328 | 269.1 | 121.9 | (109.1-135.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

260

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 12.4 | 97.1 | (50.1-169.6) |  | Male | 10 | 7.3 | 136.7 | (65.4-251.4) |
| Female | 2 | 4.7 | nc | (nc-nc) |  | Female | 7 | 5.5 | 127.6 | (51.1-262.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.9 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.4 | nc | (nc-nc) |  | Male | 4 | 6.4 | nc | (nc-nc) |
| Female | 45 | 44.1 | 102.1 | (74.5-136.6) |  | Female | 5 | 6.1 | 82.5 | (26.6-192.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 5.0 | 120.6 | (44.0-262.5) |
| Female | 0 | 1.2 | nc | (nc-nc) |  | Female | 6 | 2.5 | 240.5 | (87.8-523.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.3 | 81.2 | (38.9-149.3) |  |  |  |  |  |  |
| Female | 8 | 13.8 | 58.1 | (25.0-114.4) |  | Female | 2 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 3.1 | nc | (nc-nc) |  | Male | 3 | 4.2 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 4.8 | 104.9 | (33.8-244.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 40 | 39.8 | 100.5 | (71.8-136.9) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.0 | 134.4 | (57.9-264.9) |  | Male | 0 | 2.8 | nc | (nc-nc) |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 4 | 3.4 | nc | (nc-nc) |  | Female | 5 | 6.4 | 78.5 | (25.3-183.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 4.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.4 | nc | (nc-nc) |  | Female | 7 | 10.2 | 68.9 | (27.6-142.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 22.1 | 77.0 | (44.8-123.2) |  | Male | 139 | 151.8 | 91.6 | (77.0-108.1) |
| Female | 7 | 23.7 | 29.5 | (11.8-60.8) |  | Female | 128 | 156.2 | 82.0 | (68.4-97.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

261

# Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 7 | 10.7 | 65.2 | (26.1-134.4) |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 4 | 7.7 | nc | (nc-nc) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

262

# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 5.5 | 128.4 | (51.4-264.6) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 6 | 3.4 | 178.9 | (65.3-389.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 3 | 3.5 | nc | (nc-nc) |
| Female | 27 | 27.2 | 99.4 | (65.5-144.6) |  | Female | 3 | 3.1 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 6.4 | 93.9 | (34.3-204.4) |  |  |  |  |  |  |
| Female | 6 | 6.8 | 88.8 | (32.4-193.2) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.7 | nc | (nc-nc) |  | Male | 5 | 2.1 | 235.2 | (75.8-549.0) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 3 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 26 | 24.4 | 106.7 | (69.7-156.4) |
| Female | 1 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 3.7 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.3 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 7 | 5.2 | 134.9 | (54.1-278.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.7 | (26.0-188.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 10.5 | 66.7 | (26.7-137.4) |  | Male | 78 | 83.2 | 93.8 | (74.1-117.1) |
| Female | 5 | 11.2 | 44.7 | (14.4-104.4) |  | Female | 87 | 86.9 | 100.1 | (80.2-123.5) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

263

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 2 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 8 | 5.0 | 160.7 | (69.2-316.7) |  | Female | 1 | 0.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.1 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 5.1 | 138.6 | (55.5-285.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 3 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 2.4 | nc | (nc-nc) |  | Male | 18 | 18.5 | 97.3 | (57.6-153.7) |
| Female | 2 | 2.1 | nc | (nc-nc) |  | Female | 19 | 15.9 | 119.5 | (71.9-186.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

264